Spotlight on Family Medicine

Credits: 0.25 CME
Chronic Idiopathic Urticaria Curbside Consults ̶ Treatment Optimization: Management of Patients with Chronic Idiopathic Urticaria Refractory to H1-antagonists
Jonathan A. Bernstein, MD
Vindico

Chronic Idiopathic Urticaria Curbside Consults ̶ Treatment Optimization: Management of Patients with Chronic Idiopathic Urticaria Refractory to H1-antagonists

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the strengths and limitations of current guideline approaches to the management of chronic idiopathic urticaria (CIU).
  • Examine treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Description

Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Lang and Bernstein discuss CIU/CSU treatment options and strategies to optimize therapy for patients with refractory symptoms despite treatment with recommended first- and second-line therapy options. 

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda

Faculty

David M. Lang, MD
Professor of Medicine
Chair, Department of Allergy & Clinical Immunology
Respiratory Institute
Cleveland Clinic
Cleveland, OH

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: November 23, 2020
Expires: November 22, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is allergists, dermatologists, immunologists and other health care professionals involved in the management of patients with chronic idiopathic urticaria.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the strengths and limitations of current guideline approaches to the management of chronic idiopathic urticaria (CIU).
  • Examine treatment options for patients with CIU who fail to achieve complete symptom control with first- and second-line therapy.

Activity Description

Urticaria, a common skin condition characterized by pruritic hives, occurs in 20% to 25% of individuals within their lifetimes. Urticaria can be classified by both symptom duration and underlying etiology. Patients who experience symptom recurrence for a duration more than 6 weeks without a known cause may be diagnosed as having chronic idiopathic urticaria (CIU), also referred to as chronic spontaneous urticaria (CSU). This condition has a significant negative impact on physical functioning, work performance, emotional well-being, and overall quality of life, with an impact similar in magnitude to that experienced by patients with coronary disease who are awaiting bypass surgery. A US practice guideline issued in 2014 and an international guideline published in 2018 are available to guide the diagnosis and treatment of urticaria. These guidelines differ in select areas, and specialists need to be knowledgeable about their strengths and limitations to select optimal treatment strategies for their patients. This CME Curbside Consults series features case-based videos that address key challenges in the diagnosis and treatment of CIU/CSU. In this Curbside Consult, Drs. Lang and Bernstein discuss CIU/CSU treatment options and strategies to optimize therapy for patients with refractory symptoms despite treatment with recommended first- and second-line therapy options. 

Activity Chair

Jonathan A. Bernstein, MD
Professor of Medicine
University of Cincinnati College of Medicine
Department of Internal Medicine
Division of Immunology, Allergy Section
Editor in Chief, Journal of Asthma
Partner, Bernstein Allergy Group
Partner, Bernstein Clinical Research Center
Cincinnati, OH

Disclosure:
Royalty: CRC Press, Springer Publishing;
Intellectual Property/Patent: University of Cincinnati;
Consulting Fee: ALK, AstraZeneca, BioCryst, CSL Behring, Genentech, Merck, Novartis, Optinose, Pharming, Regeneron, Sanofi, Shire;
Speakers Bureau: ALK, AstraZeneca, CSL Behring, GlaxoSmithKline, Novartis, Optinose, Pharming, Sanofi, Shire;
Contracted Research: AstraZeneca, BioCryst, CSL Behring, Ionis, KalVista, Merck, Novartis/Genentech, Optinose, Pharming, Sanofi, Shire/Takeda

Faculty

David M. Lang, MD
Professor of Medicine
Chair, Department of Allergy & Clinical Immunology
Respiratory Institute
Cleveland Clinic
Cleveland, OH

Disclosure: No relevant financial relationships to disclose.

Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering the posttest question correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Family Medicine Presentations

0.25 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 3: A Case-Based Look at Managing Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 3: A Case-Based Look at Managing Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 13, 2021
Expires: July 13, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 13, 2021
Expires: July 13, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma
  • Construct evidence-based treatment regimens for patients with moderate-to-severe asthma to reflect symptoms, exacerbation risks, comorbidities, and treatment responses

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.75 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Start

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

1.00 CME / MOC / CC
Vindico
Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Start

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.00 AANP / CME
AKH Inc., Advancing Knowledge in Healthcare
PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

PsA+COVID-19: Augmented Reality and Patient Engagement in the Treatment of Psoriatic Arthritis

Start

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 21, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

  1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
  2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
  4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

  1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
  2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
  3. Demonstration of Augmented Reality App for Providers and Patients
  4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon


Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan


David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

  • Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
  • Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
  • Patient Presenter: David Kramer
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
  • Speaker: Eli Lilly, Janssen, Novartis, Pfizer
  • Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

  • Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 Contact Hour(s)
Released: June 21, 2021
Expires: June 21, 2022
60 minutes to complete

Accredited By

This activity is provided by Forefront Collaborative and AKH Inc., Advancing Knowledge in Healthcare.

Target Audience

The target audiences are rheumatologists and nurse practitioner (NP)/physician assistant (PA) rheumatology providers. Other clinicians who are involved in the care and treatment of patients with psoriatic arthritis (PsA) can benefit from participation in this education.

Learning Objectives

As a result of participation in this initiative, participants will increase their ability to:

  1. Use augmented reality (AR) apps for providers and patients on mechanisms of action (MOAs) of therapies for treatment of PsA.
  2. Discuss effectiveness and safety of conventional, biologic, and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for treatment of PsA.
  3. Apply evolving recommendations and clinical practice guidelines related to COVID-19 infection and vaccination to providing care to patients with PsA.
  4. Inform patients with PsA about the impact of their disease and the benefits and risks of medications in the context of COVID-19 infection and vaccination when making shared decisions about treatment plan and treatment modifications.

Activity Description

COVID-19 has impacted PsA patient care in many ways, particularly for patients with multiple comorbidities. This interactive activity reviews clinical practice guidelines addressing COVID-19 infection and vaccination that are relevant to patients with PsA, highlights effectiveness and safety of therapies for PsA, and offers a self-directed experience of building and solving patient cases to learn from making decisions and receiving immediate feedback. This activity also incorporates the patient perspective, a skill-oriented presentation on engaging patients in shared decision making, decision aids, and a demonstration of an augmented reality (AR) app on PsA for healthcare providers and patients.

Please download the ImmerseRx: Psoriatic Arthritis augmented reality app on your mobile device to gain the most benefit from participation in this activity. You may use this QR code or search for it in Google Play or the App Store.

For the best experience, use a laptop, desktop, or tablet with the Google Chrome browser.

Agenda

  1. Providing Psoriatic Arthritis Care During the COVID-19 Pandemic
  2. Using Shared Decision Making to Engage Patients With Psoriatic Arthritis to Clarify Treatment Goals in the Context of COVID-19
  3. Demonstration of Augmented Reality App for Providers and Patients
  4. Personalized Patient Cases

Faculty

Atul A. Deodhar, MD, MRCP, FACR, FACP
Professor of Medicine,
Medical Director of Rheumatology Clinics,
Division of Arthritis & Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon


Richard Martin, MD, MA
Professor of Medicine and Rheumatology,
Michigan State University College of Human Medicine
Grand Rapids, Michigan


David Kramer
Patient Presenter

Disclosure and Conflict of Interest Resolution

Educational activities provided by Forefront Collaborative and AKH must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all financial relationship(s) with ineligible companies.* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below as they were at the launch of this activity.

*The ACCME defines an ineligible company as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies—unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company.

The following individuals have indicated that they have not had, in the past 24 months, a relevant financial relationship(s) with ineligible companies to disclose:

  • Planners (Forefront Collaborative): Leah Johnson and Marianna Shershneva, MD, PhD
  • Planners (Faculty): Linda Grinnell-Merrick, MS, NP-BC
  • Patient Presenter: David Kramer
  • Planners and Reviewers (AKH Inc): Dorothy Caputo, MA, BSN, RN, and Bernadette Marie Makar, MSN, APRN, BC, NP-C

The following individuals have disclosed that they have had a financial relationship in the past 24 months that has been deemed relevant to this activity. All relevant financial relationships have been mitigated:

Faculty Presenter: Atul A. Deodhar, MD, MRCP, FACR, FACP

  • Consultant: Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB
  • Speaker: Eli Lilly, Janssen, Novartis, Pfizer
  • Independent contractor (including contracted research): AbbVie, Amgen, Celgene, Eli Lilly, GlaxoSmithKline, Galapagos, Novartis, Pfizer, UCB

Faculty Presenter: Richard Martin, MD, MA

  • Contracted Research/Current Clinical Trials: AbbVie, Eli Lilly

Faculty Planner: Alvin F. Wells, MD, PhD, FACR

  • Speakers Bureau: AbbVie, Amgen, BMS, Eli Lilly, Novartis, Pfizer, Sanofi

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Physicians
Forefront Collaborative designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Forefront Collaborative. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803.

This activity is approved for 1.0 contact hour (which includes 0.25 hours of pharmacology).

Statement of Commercial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Disclaimer Statement/Disclosure of Unlabeled Use

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative, AKH and Lilly.

The content of this activity was independently peer reviewed by two reviewers. The reviewers of this activity have no relevant financial relationships to disclose.

This continuing medical education activity will include references to unlabeled or unapproved uses of drugs.

Contact Information for Questions About the Activity

Thank you for your participation! We value your opinion. If you have any feedback or questions about this educational activity, please contact info@forefrontcollab.com.

0.25 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 1: Evaluating Patients With Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 1: Evaluating Patients With Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 18, 2021
Expires: June 18, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC., Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 18, 2021
Expires: June 18, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:

  • Evaluate patients with moderate-to-severe asthma for symptom control and disease phenotypes

Faculty

Jonathan Corren, MD
Associate Clinical Professor of Medicine and Pediatrics
David Geffen School of Medicine
University of California, Los Angeles
Medical Director, Jonathan Corren M.D. and Associates
Los Angeles, California


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Jonathan Corren, MD
Consulting Fees: AstraZeneca plc, Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC
Contracted Research: AstraZeneca plc, Genentech, Inc., Novartis Pharmaceuticals Corporation, OptiNose USS, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC., Teva Pharmaceuticals Industries Ltd.
Speakers’ Bureau: AstraZeneca plc, Genentech, Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part IV: Patient Cases: Putting Evidence Into Perspective

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Summarize the current guidelines and recommendations for the treatment of PAH
  • Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Summarize the current guidelines and recommendations for the treatment of PAH
  • Develop individualized treatment regimens based on the multidisciplinary approach to care for PAH that takes into account treatment goals, short-and-long-term assessment, and comorbidities in order to improve patient outcomes

Faculty

Sonja Bartolome, MD, FCCP
Professor, Pulmonary and Critical Care Medicine
Associate Chief Quality Officer
UT Southwestern Medical Center
Dallas, TX

Dr. Bartolome discloses the following:
Consulting Fees: Janssen

Ronald J. Oudiz, MD, FACP, FACC, FCCP
Investigator, The Lundquist Institute
Professor of Medicine, David Geffen School of Medicine at UCLA
Director, Liu Center for Pulmonary Hypertension, The Lundquist Institute
Torrance, CA

Dr. Oudiz discloses the following:
Consulting Fees: Gilead, Gossamer, Insmed, JnJ, Liquidia, Respira, United Therapeutics, V-Wave
Fees for Non-CME Services Received Directly from a Commercial Interest: JnJ, United Therapeutics, V-Wave
Contracted Research: AADi, Gossamer, Insmed, JnJ, Liquidia, United Therapeutics, V-Wave

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2782-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part I: Screening and Diagnosis of PAH

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
  • Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients

Faculty

Jean Elwing, MD, FCCP
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH

Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer, Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer

Marc Humbert, MD, PhD
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France

Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2779-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Identify patients with PAH based on symptoms, risk factors, and screening strategies outlined in evidence-based guidelines
  • Utilize evidence-based diagnostic methods to effectively and timely diagnose PAH patients

Faculty

Jean Elwing, MD, FCCP
Professor of Medicine
University of Cincinnati
Pulmonary Hypertension Program
Cincinnati, OH

Dr. Elwing discloses the following:
Consulting Fees: United Therapeutics, Acceleron, Liquidia, Altavant, Bayer, Gossamer Bio
Contracted Research: Actelion, Acceleron, Reata, United Therapeutics, Liquidia, Phase Bio, Complexa, Gossamer Bio, Bayer

Marc Humbert, MD, PhD
Centre National de Référence de l’Hypertension Pulmonaire Sévère
Hôpital Bicêtre
Assistance Publique – Hôpitaux de Paris
Université Paris-Saclay
Le Kremlin-Bicêtre, France

Dr. Humbert discloses the following:
Consulting Fees: Acceleron, Bayer, GSK, Janssen, Merck
Contracted Research: Acceleron, Bayer, GSK, Janssen, Merck

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2779-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part II: PAH Treatment - Goals, Therapeutic Options, and Guidelines

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
  • Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
  • Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Incorporate risk stratification methods for selecting and modifying therapy in patients with PAH
  • Evaluate the efficacy and safety of current and emerging therapeutic options for PAH
  • Review the evidence for initiating combination therapy in patients with PAH

Faculty

Nazzareno Galiè, MD
Professore Ordinario di Cardiologia
Direttore U.O.C. di Cardiologia, IRCCS-Policlinico di S.Orsola, Bologna
Direttore della Scuola di Specializzazione in
Malattie dell’Apparato Cardiovascolare
Bologna, Italy

Dr. Galiè discloses the following:
Consulting Fees: Janssen, Actelion, Ferrer, Pfizer
Contracted Research: Janssen

Gerald Simonneau, MD
French Reference Center for PH
Emeritus Professor University Paris-Saclay
Paris, France

Dr. Simonneau discloses the following:
Consulting Fees: Actelion, Bayer, MSA
Fees for Non-CME Services Received Directly from a Commercial Interest: Actelion, Bayer, MSA

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2780-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

1.00 CME / CNE / CPE
The Postgraduate Institute for Medicine
Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Navigating the Complexity of Pulmonary Arterial Hypertension: Advances in the Diagnosis and Management – Part III: Latest Data on PAH Treatment Approaches

Start

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

Activity Details

Free CME/CNE/CPE
1 AMA PRA Category 1 Credit(s)
1 contact hour(s)
Released: June 17, 2021
Expires: June 17, 2022
60 minutes to complete

Accredited By

Target Audience

The activity will target a global audience of cardiologists, lipidologists, primary care physicians, nurses, physician assistants, and pharmacists.

Learning Objectives

  • Evaluate the potential role of cardiac MRI metrics and other cardiac endpoints in PAH risk stratification
  • Interpret the results of recent trials for transition of PAH therapies
  • Summarize real-world data from PAH registries and their potential implications for management

Faculty

Vallerie V. McLaughlin, MD
Professor of Cardiovascular Medicine
Director of the Pulmonary Hypertension Program
University of Michigan
Ann Arbor, MI

Dr. McLaughlin discloses the following:
Consulting Fees: Acceleron, Actelion, Altavant, Caremark, Civi Biopharma, Gossamer, Liquida, United Therapeutics
Contracted Research: Acceleron, Actelion, Gilead, Sonivie, Reata, United Therapeutics

Stephan Rosenkranz, MD
Professor
Department of Cardiology, Pulmonology, and Intensive Care Medicine
Center for Molecular Medicine Cologne (CMMC)
Cologne Cardiovascular Research Center (CCRC)
Heart Center at the University of Cologne
Cologne, Germany

Dr. Rosenkranz discloses the following:
Consulting Fees and Fees for Non-CME Services Received Directly from a Commercial Interest: Abbott, Acceleron, Actelion, Bayer, BMS, MSD, Novartis, Pfizer, Ferrer, United Therapeutics, Vifor
Contracted Research to Institution: Actelion, AstraZeneca, Bayer, Novartis, Pfizer, Janssen

Conflict of Interest Policy/Disclosure Statement

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Planners and Managers
The PIM planners and managers have nothing to disclose.
The CMHC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hour(s). Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

This is a knowledge-based activity. Universal Activity Numbers (UAN): # JA4008162-9999-21-2781-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

Statement of Commercial Support

Supported by an educational grant from Merck Sharp & Dohme Corp.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about the accreditation of this activity, please visit www.pimed.com.

0.25 CME
Global Education Group
Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 2: Biologics for Moderate-to-Severe Asthma

Where Are We Now in Moderate-to-Severe Asthma? From Comprehensive Patient Evaluations to Individualized Evidence-Based Care—Module 2: Biologics for Moderate-to-Severe Asthma

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 11, 2021
Expires: June 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma

Faculty

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: June 11, 2021
Expires: June 11, 2022
15 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Statement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Target Audience

The educational design of this activity addresses the needs of allergists, pulmonologists, and other clinicians involved in the ongoing management of patients with moderate-to-severe asthma.

Statement of Need

Asthma-related symptoms and exacerbations result in almost 2 million emergency department visits each year.1,2 Importantly, severe disease accounts for an outsized proportion of asthma-related mortality, morbidity, and health care costs.3-5 Children with severe asthma, in particular, are at increased risk for recurrent, life-threatening exacerbations and medication-related adverse outcomes.6 Further, parents of children with severe disease report substantial psychosocial and quality-of-life impairments.7

In this 4-part CME Snapshot™ series, expert faculty will examine best practices for the assessment and phenotypic classification of moderate-to-severe asthma in adult and pediatric patients as well as evaluate biomarkers that may be used to distinguish disease endotypes and guide treatment selection. Following a review of the latest evidence surrounding biologic therapies for moderate-to-severe asthma and their use in targeting specific disease endotypes, expert faculty will walk participants through challenging clinical case scenarios—discussing the application of evidence to the practice of precision medicine in asthma care. Faculty will also share their clinical pearls on how to best engage patients in a shared decision-making manner when selecting among biologic treatment options. After completion of the activity, participants will be well-equipped to translate the latest evidence and expert recommendations for individualized asthma management to next-day practice.

References

  1. Centers for Disease Control and Prevention. Asthma Facts: CDC’s National Asthma Control Program Grantees, 2013. https://www.cdc.gov/asthma/pdfs/asthma_facts_program_grantees.pdf
  2. Nunes C, et al. Asthma Res Pract. 2017;3:1.
  3. Levy ML. Breathe (Sheff). 2015;11(1):14-24.
  4. Bahadori K, et al. BMC Pulm Med. 2009;9:24.
  5. Pijnenburg MW, Fleming L. Lancet Respir Med. 2020;8(10):1032-1044.
  6. Moorman JE, et al. Vital Health Stat 3. 2012;35:1-58.
  7. Boeschoten SA, et al. Pediatr Pulmonol. 2020;55(11):2883-2892.

Educational Objective

After completing this activity, the participant should be better able to:
  • Describe the clinical profiles of and prescribing considerations for biologic therapies in the treatment of moderate-to-severe asthma

Faculty

Monica Kraft, MD
Professor, Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Integritas Communications Contact Information

For all other questions about this activity, please contact Integritas Communications at info@exchangecme.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, view the educational content, score 100% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Monica Kraft, MD
Consultant/Independent Contractor: AstraZeneca plc, sanofi-aventis U.S. LLC
Grant/Research Support: AstraZeneca plc, Chiesi USA, Inc., sanofi-aventis U.S. LLC

The planners and managers have the following relevant financial relationships with ineligible companies:

Lindsay Borvansky: Nothing to disclose
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Celeste Collazo, MD: Nothing to disclose
Rose O’Connor, PhD, CHCP: Nothing to disclose

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Pages